-
公开(公告)号：US09079918B2
公开(公告)日：2015-07-14
申请号：US14448058
申请日：2014-07-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mimi L. Quan , Carl P. Decicco , James R. Corte , Cailan Wang
IPC: C07D487/06 , C07D487/08 , C07D471/08 , C07D471/18 , C07D498/08
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
2.发明授权公开(公告)号：US09458110B2
公开(公告)日：2016-10-04
申请号：US14770500
申请日：2014-02-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mimi L. Quan , Zilun Hu , Cailan Wang , Peter W. Glunz
IPC: C07D231/12 , C07D401/12 , C07D417/12 , C07D403/12 , C07D217/12 , C07D405/12 , C07D513/04 , C07D231/56 , C07D413/12
CPC classification number: C07D231/12 , C07D217/12 , C07D231/56 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D513/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US20150266894A1
公开(公告)日：2015-09-24
申请号：US14733996
申请日：2015-06-09
Applicant: Bristol-Myers Squibb Company
Inventor： Mimi L. Quan , Carl P. Decicco , James R. Corte , Cailan Wang
IPC: C07D498/08 , C07D487/18 , C07D471/18 , C07D487/08
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号：US20140343276A1
公开(公告)日：2014-11-20
申请号：US14448058
申请日：2014-07-31
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mimi L. Quan , Carl P. Decicco , James R. Corte , Cailan Wang
IPC: C07D498/08 , C07D487/08
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
公开(公告)号：US09745313B2
公开(公告)日：2017-08-29
申请号：US15246813
申请日：2016-08-25
Applicant: Bristol-Myers Squibb Company
Inventor： Mimi L. Quan , Carl P. Decicco , James R. Corte , Cailan Wang
IPC: C07D487/18 , C07D487/04 , C07D487/08 , C07D498/08 , C07D487/06 , C07D487/16 , C07D498/06 , C07D471/18 , C07D471/14 , C07D487/14 , C07D498/04
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
Patent Agency Ranking
公开(公告)号：US09453029B2
公开(公告)日：2016-09-27
申请号：US14733996
申请日：2015-06-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mimi L. Quan , Carl P. Decicco , James R. Corte , Cailan Wang
IPC: C07D487/06 , C07D498/06 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/18 , C07D498/08 , C07D487/16
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
-
公开(公告)号：US20160152627A1
公开(公告)日：2016-06-02
申请号：US14900228
申请日：2014-07-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Mimi L. Quan , Zilun Hu , Cailan Wang
IPC: C07D491/052 , C07D471/04
CPC classification number: C07D491/052 , C07D471/04 , C07D498/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
8.发明申请公开(公告)号：US20140243338A1
公开(公告)日：2014-08-28
申请号：US14192955
申请日：2014-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Mimi L. Quan , Zilun Hu , Cailan Wang
IPC: C07D231/12 , C07D401/12 , C07D417/12
CPC classification number: C07D231/12 , C07D217/12 , C07D231/56 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/12 , C07D513/04
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
Abstract translation: 本发明提供式（I）的化合物或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性的ROCK抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其治疗心血管，平滑肌，肿瘤学，神经病理学，自身免疫性，纤维化和/或炎症性疾病的方法。
-
公开(公告)号：US10730858B2
公开(公告)日：2020-08-04
申请号：US16315674
申请日：2017-07-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zilun Hu , Cailan Wang , Mimi L. Quan , Peter W. Glunz
IPC: C07D403/10 , C07D403/14 , C07D405/14 , C07D487/04 , C07D495/04 , C07D401/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D401/10
Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
-
公开(公告)号：US20160362414A1
公开(公告)日：2016-12-15
申请号：US15246813
申请日：2016-08-25
Applicant: Bristol-Myers Squibb Company
Inventor： Mimi L. Quan , Carl P. Decicco , James R. Corte , Cailan Wang
IPC: C07D487/04 , C07D487/14 , C07D471/14 , C07D498/04
CPC classification number: C07D487/04 , C07D471/14 , C07D471/18 , C07D487/06 , C07D487/08 , C07D487/14 , C07D487/16 , C07D487/18 , C07D498/04 , C07D498/06 , C07D498/08
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Abstract translation: 或其立体异构体，互变异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是选择性因子XIa抑制剂或fXIa和血浆激肽释放酶的双重抑制剂。 本发明还涉及包含这些化合物的药物组合物和使用其制备血栓栓塞和/或炎症性疾病的方法。
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.029 seconds)
